Keen Vision Acquisition Corporation (KVAC)
KVAC moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How KVAC actually reacts to news — the realized, point-in-time move the market made, measured across 91 labeled events over the last three years with zero look-ahead.
KVAC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 15% | 33 |
| 30-min | 0.00% | 19% | 36 |
| 60-min | 0.00% | 35% | 40 |
| to close | 0.00% | 39% | 49 |
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when KVAC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KVAC's baseline. Nothing else.
Recent KVAC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Keen Vision Acquisition For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | — | -3.36% | |
| Form DEFA14A Keen Vision Acquisition | SEC filing · Form DEFA14A | SEC EDGAR | — | -3.36% | |
| Form 8-K Keen Vision Acquisition For: Jul 21 | SEC filing · Form 8-K | SEC EDGAR | +2.87% | -10.78% | |
| Form DEF 14A Keen Vision Acquisition For: Jul 21 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form PRE 14A Keen Vision Acquisition For: Jun 22 | SEC filing · Form PRE | SEC EDGAR | — | — | |
| Form 10-Q Keen Vision Acquisition For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | — | +0.17% | |
| Form 10-K Keen Vision Acquisition For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Feb 26 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Jan 22 | SEC filing · Form 8-K | SEC EDGAR | +0.08% | -1.34% | |
| Form DEFA14A Keen Vision Acquisition | SEC filing · Form DEFA14A | SEC EDGAR | — | +0.09% | |
| Form 8-K Keen Vision Acquisition For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form ARS Keen Vision Acquisition For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | — | — | |
| Form DEF 14A Keen Vision Acquisition For: Jan 22 | SEC filing · Form DEF | SEC EDGAR | — | — | |
| Form PRE 14A Keen Vision Acquisition For: Dec 22 | SEC filing · Form PRE | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.17% | |
| Form 10-Q Keen Vision Acquisition For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Oct 21 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Sep 19 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Aug 27 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Keen Vision Acquisition For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.17% | |
| Medera and University of Kansas Medical Center Announce First Patient Treated in Pioneering Gene Therapy Trial for Duchenne Muscular Dystrophy Associated Cardiomyopathy | Press release | GlobeNewswire | +0.00% | +0.00% | |
| Form DEF 14A Keen Vision Acquisition For: Jul 22 | SEC filing · Form DEF | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Keen Vision Acquisition For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -0.79% | -0.44% | |
| Medera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome | Press release | GlobeNewswire | +0.09% | +0.26% | |
| Form PRE 14A Keen Vision Acquisition For: Jun 23 | SEC filing · Form PRE | SEC EDGAR | +0.09% | +0.26% | |
| Medera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025 | Press release | GlobeNewswire | -0.09% | -0.09% | |
| Form 8-K Keen Vision Acquisition For: May 20 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress | Press release | GlobeNewswire | +0.00% | +0.18% | |
| Form 10-Q Keen Vision Acquisition For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Apr 25 | SEC filing · Form 8-K | SEC EDGAR | — | -0.12% | |
| Medera Presented Updated Results from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at 2025 HFpEF Summit | Press release | GlobeNewswire | — | -0.09% | |
| Form 8-K Keen Vision Acquisition For: Mar 24 | SEC filing · Form 8-K | SEC EDGAR | — | +0.27% | |
| Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction | Press release | GlobeNewswire | — | — | |
| Medera Completes Patient Dosing in Phase 1/2a MUSIC-HFrEF Trial of SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction | Press release | GlobeNewswire | — | — | |
| Form 10-K Keen Vision Acquisition For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| Form 8-K Keen Vision Acquisition For: Feb 24 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht | Press release | GlobeNewswire | +0.00% | -0.09% | |
| Form 8-K Keen Vision Acquisition For: Jan 22 | SEC filing · Form 8-K | SEC EDGAR | — | +0.18% | |
| Form 8-K Keen Vision Acquisition For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Medera’s Novoheart and Curi Bio Partner to Transform Human-Based Cardiac Drug Screening | Press release | GlobeNewswire | — | — | |
| Medera’s Novoheart Releases Latest Cardiac Screening Innovation CTScreen v1.5 to Advance High-Throughput, Automated Human-Based Drug Testing | Press release | GlobeNewswire | — | — | |
| Form 8-K Keen Vision Acquisition For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form 10-Q Keen Vision Acquisition For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | — | -0.18% | |
| Medera Announces Publication of Study Utilizing Machine Learning to Enhance Next-Generation Drug Screening with Human mini-Heart Technology | Press release | PR Newswire | +0.00% | +0.00% | |
| Form 8-K Keen Vision Acquisition For: Oct 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.00% | |
| Form 8-K Keen Vision Acquisition For: Oct 24 | SEC filing · Form 8-K | SEC EDGAR | — | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KVAC section they belong to.
Where else KVAC is measured.
KVAC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Keen Vision Acquisition Corporation's median reaction calculated?
Every labeled KVAC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 91 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 19% of KVAC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KVAC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.